AI Multimodal Model for Predicting CRPC Progression Risk (NCT07658573) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
AI Multimodal Model for Predicting CRPC Progression Risk
China500 participantsStarted 2025-06-01
Plain-language summary
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
Who can participate
Age range
18 Years – 80 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months).
Exclusion Criteria:
* (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prediction of CRPC Progression Risk in the ADT Treatment Group
Timeframe: Minimum 24 months of follow-up
2
Prediction of CRPC Progression Risk in the Radical Prostatectomy Group